The non‐peptide neurokinin1 receptor antagonist, RP 67580, blocks neurogenic plasma extravasation in the dura mater of rats
Open Access
- 1 January 1993
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 108 (1) , 11-12
- https://doi.org/10.1111/j.1476-5381.1993.tb13432.x
Abstract
A non-peptide neurokinin1 (NK1) receptor antagonist, RP 67580, that is selective for the rodent subtype of the NK1 receptor, dose-dependently reduced plasma extravasation in the dura mater produced by electrical stimulation of the trigeminal ganglion in rats, with an ID50 of 0.6 μg kg−1. Its enantiomer RP 68651 was some 400 fold less active. The results indicate that neurogenic plasma extravasation within the dura mater is NK1 receptor-mediated and suggest that NK1 receptor antagonists may have a role as antimigraine agents.Keywords
This publication has 5 references indexed in Scilit:
- 5-Hydroxytryptamine receptor agonists for the abortive treatment of vascular headaches block mast cell, endothelial and platelet activation within the rat dura mater after trigeminal stimulationBrain Research, 1992
- Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraineTrends in Pharmacological Sciences, 1992
- Investigation into species variants in tachykinin NK1 receptors by use of the non‐peptide antagonist, CP‐96,345British Journal of Pharmacology, 1991
- The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura materBritish Journal of Pharmacology, 1990
- Ergot alkaloids block neurogenic extravasation in dura mater: Proposed action in vascular headachesAnnals of Neurology, 1988